BioCryst Pharmaceuticals
BCRX
124 hedge funds and large institutions have $740M invested in BioCryst Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 21 closing their positions.
152% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $6.5M
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 123 → 124 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less capital invested
Capital invested by funds: $938M → $740M (-$198M)
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$33.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$16M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$8.86M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.94M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$18.8M |
| 3 |
Millennium Management
New York
|
-$12.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.68M |
| 5 |
VM
VHCP Management
New York
|
-$5.58M |
BCRX Hedge Fund Activity: Q3 2015 in Review
124 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2015, worth a combined $740M — down 21% from $938M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BCRX positions and 21 closed out — a net gain of 1 holder — while 43 added to existing stakes and 41 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $33.8M. The largest seller was Fidelity Investments, cutting an estimated $25.3M.
- 124 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2015, up from 123 in Q2 2015.
- Funds reported $740M of BioCryst Pharmaceuticals stock for Q3 2015, down 21% quarter-over-quarter.
- 22 funds opened new BioCryst Pharmaceuticals positions in Q3 2015 and 21 closed out, a net change of +1 holder.
- The largest BioCryst Pharmaceuticals buyer in Q3 2015 was Baker Bros. Advisors, an estimated $33.8M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2015 was Fidelity Investments, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2015.